Premium
Intravitreal bevacizumab (Avastin) treatment in neovascular age‐related macular degeneration: 6 months results
Author(s) -
CIMBALAS A,
BAGDONIENE R,
SIRTAUTIENE R,
LIVEIKIENE A,
ASOKLIS R
Publication year - 2008
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2008.625.x
Subject(s) - medicine , bevacizumab , macular degeneration , ophthalmology , visual acuity , uveitis , surgery , chemotherapy
Purpose To study the visual and anatomic outcome of the intravitreal bevacizumab injection in the treatment of neovascular age‐related macular degeneration (AMD). Methods 86 eyes of 79 patients (mean age: 74.9) who received one or more intravitreal bevacizumab injections for neovascular AMD and had a follow‐up of at least 6 months were analyzed retrospectively. Visual acuity (VA), optical coherence tomography (OCT) macular thickness,pretreatments and number of the needed treatments were evaluated. Results Results showed a mean visual acuity of 0.14 before the first intravitreal injection with bevacizumab. Six months after the first injection, patients VA increased by 0.18, i.e. they gain 0.04 lines of Snellen (P = 0,003). The mean number of treatments needed at this time was 3.3 (range: 1 to 5 injections). Central retinal thickness (CTR) assessed with OCT was 354±187 µm before the first treatment and decreased by 150±169 µm after 6 months (P < 0,001). 14% of the patients needed a treatment at the 6‐months follow‐up. One patient presented uveitis several days following intravitreal injection of bevacizumab. Conclusion Six months follow‐up of the intravitreal bevacizumab in the eyes with neovascular AMD showed stabilization of the visual acuity.